Medical Affairs
Marinus is committed to advancing science and research in a range of seizure disorders, and having a positive impact on the lives of patients and caregivers. We strive to develop safe, effective, and innovative therapies, and provide support and education to the rare disease community.
Learn more about the ways that Marinus is shaping the future of treatments for seizure disorders
Marinus is planning to offer the following programs to further support patients affected by seizure disorders.
Educational Grants
Dedication to improving the lives of patients and caregivers
Compassionate Use
We take our responsibility to act as a true partner with the medical community very seriously and are committed to ensuring our innovations reach as many patients as possible, as quickly as possible.
Support & Sponsorship
Supporting activities and programs focused on seizure disorders
BIO Guiding Principles for Interaction with Patient Advocacy Organizations
At Marinus, integrity and trust are of the utmost importance. That is why we abide by BIO patient engagement principles as we work with patient advocacy organizations to better support the patients we serve, and to help raise awareness and understanding of the unmet needs we work to address. You can learn more about these principles here.
Educational Resources
Background on Status Epilepticus
Kapur et al. 2019 Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
Holtkamp et al. 2005 Predictors and Prognosis of Refractory Status Epilepticus
Treated in a Neurological Intensive Care Unit
Hocker et al. 2013 Predictors of Outcome in Refractory Status Epilepticus
Chamberlain et al. 2020 Efficacy of levetiracetam, fosphenytoin, and valproate for
established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial
Saporito et al. 2019 Intravenously Administered Ganaxolone Blocks DiazepamResistant Lithium-Pilocarpine–Induced Status Epilepticus in Rats: Comparison with Allopregnanolones
Background on CDKL5 Deficiency Disorder
Amin et al. 2022– International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder
Olson et al. 2019 Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review
Demarest et al. 2019 CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development
Background on Tuberous Sclerosis Complex
Di Michele et al. 2003 GABAA receptor active steroids are altered in epilepsy patients with tuberous sclerosis
To contact medical information, report an adverse event, or product quality complaint, please contact Marinus Medical Information at medinfo@marinuspharma.com or call 1-844-MARINUS.